Comparison To Peers: LexinFintech Holdings Ltd. (LX), InVivo Therapeutics Holdings Corp. (NVIV)

You should consider shares of LexinFintech Holdings Ltd. (NASDAQ:LX) and InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) if you are looking for a great stocks to invest in. Starting with the LX shares, which traded at $14.05 at the close of the recent session, gaining 5.32%. On Tuesday, the company’s shares shed $0.71 from its value which represented in intraday trading. The stock is now 1.15% higher in year-to-date (YTD) trading. LX’s intraday high was $14.40 while its lowest price touched $13.7892. The stock’s 52-week high price is $16.93, which means the current price is at -17.01%. In terms of trading activity, the daily trading volume rose to 2427502 against 200-day average trading volume of 1,266,893 shares.

What are analyst forecasts for LexinFintech Holdings Ltd. (NASDAQ:LX)?

At a consensus rating of 5.00, LX is trending as a streaking Strong Buy, as it has been the case a month ago when 2 analysts called it a Strong Buy. Two months ago, 3 analysts recommended, on average, that LX stock is a Moderate Buy. The Financial company’s shares’ overall bullish trend saw it close lower on Tuesday compared to its opening price of $13.79 on the day.

Forecasts for LexinFintech Holdings Ltd. (NASDAQ:LX) give the stock a fair value for the growth of 88.53% from its last price. The 12-month price forecast for the stock by analysts puts the stock’s mean price target at $122.54, which means the price per share could rise by nearly $108.49. The price range target is between a low of $94.55 and a high of $167.16. The stock would need to gain by about $91.59 to hit the estimated high or 0.6% from its 12-month low.

The consensus among 10 analysts is that it is a good time for one to Buy in the LexinFintech Holdings Ltd. 8 analysts rate LX as a Buy, with 0 of 10 analysts rate it as a Sell. 0 have valued the stock as Overweight and 2 have recommended that investors Hold.

LexinFintech Holdings Ltd. (NASDAQ:LX) Upgrades and Downgrades

In terms of rating changes, Credit Suisse on October 09, 2019, Initiated LexinFintech Holdings Ltd. (LX) at Outperform. Analysts at Morgan Stanley have assigned a Equal-Weight rating for the stock in their research note on December 11, 2018. Moreover, Goldman analysts issued a rating of Buy for the stock on November 23, 2018. On June 13, 2018, the stock earned a Neutral rating due to an analyst call from Goldman.

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) adds -$0.03 on Tuesday

The NVIV stock has tanked -9.76% year-to-date and is currently trading at $0.20, which is -88.32% below its 52-week high. The company shares lost -12.21% on the day and have risen nearly 64.87% off a low hit. As of 02/04/20, this stock has fallen -22.56% during the week and closed at $0.23 in the previous session. However, recent InVivo Therapeutics Holdings Corp. stock performance shows that NVIV shares are -13.63% down over the last month, and -51.94% down for the last three months.

Earnings per share (EPS) estimates for the current quarter are -$0.34, with the trailing 12-month share earnings at -$1.18. The ratio is expected to be up by 74.20% for the current year 2019 and 39.70% for next year. But will the NVIV stock surprise in the current quarter results, where the -$0.29 actual EPS reported on 9/29/2019 surprised by 12.10% or was higher by $0.04 from the estimated -$0.33.

Who owns shares in InVivo Therapeutics Holdings Corp. (NVIV)?

Let’s briefly focus on the share ownership of the InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) stock, where we find that 13.74% of shares are held by institutions.

NVIV Insider Activity

Insider activity can also give a signal in terms of price direction. Looking at InVivo Therapeutics Holdings Corp. (NVIV), a total of 5229 shares have been sold by insiders over the last 6 months while 116500 shares were added in the same time span. On 6/04/2019, Corporate Officer by the name Toselli Richard sold 5229.0 shares worth $5100.0 at the price of $0.97 per share. Filings also show that Toselli Richard sold a total of 95.0 shares on 2/18/2019 valued at $133.95. Since the last insider activity, the company’s share price has dropped -85.61%.